Improving Therapy for Refractory Mantle Cell Lymphoma Using Small Molecule Inhibitors Vorinostat and Palbociclib to Target Histone Deacetylase and Cyclin Dependent Kinase 4/6

被引：0
|
作者：
Hatch, Nathan [1 ]
Chaturvedi, Nagendra [2 ]
Kling, Mathew [2 ]
Joshi, Shantaram [3 ]
机构：
[1] Wayne State Coll, Life Sci, Wayne, NE USA
[2] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE USA
[3] Univ Nebraska Med Ctr, Omaha, NE 68198 USA
来源：
FASEB JOURNAL | 2017年 / 31卷
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
lb118
引用
收藏
页数：1
相关论文
共 16 条
  • [1] Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/ Refractory Mantle Cell Lymphoma
    Malarikova, Diana
    Jorda, Radek
    Dolnikova, Alexandra
    Havranek, Ondrej
    Pokorna, Eva
    Kazantsev, Dmitry
    Sovilj, Dana
    Helman, Karel
    Klanova, Magdalena
    Andera, Ladislav
    Strnad, Miroslav
    Chiron, David
    Trneny, Marek
    Klener, Pavel
    BLOOD, 2022, 140 : 5996 - 5997
  • [2] Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BCL2 Inhibitor Venetoclax in Experimental Models of Chemotherapy Refractory Mantle Cell Lymphoma
    Malarikova, Diana
    Jorda, Radek
    Dolnikova, Alexandra
    Pokorna, Eva
    Kazantsev, Dmitry
    Havranek, Ondrej
    Helman, Karel
    Klanova, Magdalena
    Strnad, Miroslav
    Trneny, Marek
    Klener, Pavel, Jr.
    BLOOD, 2021, 138
  • [3] A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma Role of cyclin-dependent kinase inhibitors
    Tula-Sanchez, Ana A.
    Havas, Aaron P.
    Alonge, Peter J.
    Klein, Mary E.
    Doctor, Samantha R.
    Pinkston, William
    Glinsmann-Gibson, Betty J.
    Rimsza, Lisa M.
    Smith, Catharine L.
    CANCER BIOLOGY & THERAPY, 2013, 14 (10) : 949 - 961
  • [4] Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response
    Nomanbhoy, Tyzoon K.
    Sharma, Geeta
    Brown, Heidi
    Wu, Jiangyue
    Aban, Arwin
    Vogeti, Subha
    Alemayehu, Senait
    Sykes, Maria
    Rosenblum, Jonathan S.
    Kozarich, John W.
    BIOCHEMISTRY, 2016, 55 (38) : 5434 - 5441
  • [5] Cyclin-dependent kinase 4/6 inhibitors palbociclib or ribociclib combined with endocrine therapy and radiation therapy for patients with metastatic breast cancer
    Ratosa, I.
    Scoccimarro, E.
    Dominici, L.
    Orazem, M.
    Steinacher, M.
    Aquilano, M.
    Cerbai, C.
    Desideri, I.
    Marinko, T.
    Livi, L.
    Meattini, I.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S66 - S66
  • [6] Combination efficacy of HDAC inhibitor vorinostat and CDK-4/6 dual inhibitor palbociclib against therapy-resistant mantle cell lymphoma
    Chaturvedi, Nagendra K.
    Hatch, Nathan D.
    Sutton, Garrett L.
    Kling, Matthew J.
    Vose, Julie M.
    Joshi, Shantaram S.
    CANCER RESEARCH, 2017, 77
  • [7] Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion
    Malarikova, Diana
    Jorda, Radek
    Kupcova, Kristyna
    Senavova, Jana
    Dolnikova, Alexandra
    Pokorna, Eva
    Kazantsev, Dmitry
    Nozickova, Kristina
    Sovilj, Dana
    Bellanger, Celine
    Chiron, David
    Andera, Ladislav
    Krystof, Vladimir
    Strnad, Miroslav
    Helman, Karel
    Klanova, Magdalena
    Trneny, Marek
    Havranek, Ondrej
    Klener, Pavel
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [8] Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion
    Diana Malarikova
    Radek Jorda
    Kristyna Kupcova
    Jana Senavova
    Alexandra Dolnikova
    Eva Pokorna
    Dmitry Kazantsev
    Kristina Nozickova
    Dana Sovilj
    Celine Bellanger
    David Chiron
    Ladislav Andera
    Vladimir Krystof
    Miroslav Strnad
    Karel Helman
    Magdalena Klanova
    Marek Trneny
    Ondrej Havranek
    Pavel Klener
    Experimental Hematology & Oncology, 13
  • [9] The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4
    Kubo, A
    Nakagawa, K
    Varma, RK
    Conrad, NK
    Cheng, JQ
    Lee, WC
    Testa, JR
    Johnson, BE
    Kaye, FJ
    Kelley, MJ
    CLINICAL CANCER RESEARCH, 1999, 5 (12) : 4279 - 4286
  • [10] The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin dependent kinase (CDK) 4.
    Kubo, A
    Nakagawa, K
    Varma, RK
    Conrad, NK
    Cheng, JQ
    Lee, WC
    Testa, JR
    Johnson, BE
    Kaye, FJ
    Kelley, MJ
    CLINICAL CANCER RESEARCH, 1999, 5 : 3755S - 3756S
12